Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Semax Peptide Studies — What the Research Actually Shows

Semax Peptide Studies — What the Research Actually Shows Semax Research: What the Studies Actually Show Semax is a synthetic peptide derived from a fragment of ACTH, with a large research literature in rodent neuroprotection and brain gene expression. What the

By Recovery & Performance Peptides Editorial Team

Semax Peptide Studies — What the Research Actually Shows

Semax Research: What the Studies Actually Show

Semax is a synthetic peptide derived from a fragment of ACTH, with a large research literature in rodent neuroprotection and brain gene expression. What the studies report — mostly in rats.

Research-use-only context. This article summarizes published third-party scientific literature — the large majority of it conducted in cultured cells or animal models. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. American Peptides products are sold strictly for in vitro laboratory research and are not for human or veterinary use.

Semax has an unusually large research literature for a peptide, much of it from Russian institutions where it was developed. This summary surveys what the peer-reviewed studies report, what models they use, and where the human evidence stands by international standards. For the format used across this series, see our BPC-157 research review.

What semax is

Semax is a synthetic peptide based on a fragment of adrenocorticotropic hormone — the ACTH(4-7) sequence extended with a Pro-Gly-Pro tail (often written ACTH(4-7)PGP, an analog of the ACTH(4-10) region). It is studied for effects on the central nervous system without the hormonal (corticotropic) activity of full ACTH.

What the research reports

A substantial body of rat studies examines semax in cerebral ischemia (stroke) models. Genome-wide transcriptional analyses report effects on genes related to the immune and vascular systems in rat brain ischemia; a 2021 proteomics study reported a protective protein-expression profile in a rat ischemia-reperfusion model. More recent work extends to spinal-cord-injury models in mice (2025) and Alzheimer’s-disease animal models (2025), and some studies frame semax as a copper-chelating peptide that affects amyloid aggregation in artificial-membrane models. These findings are, with few exceptions, in rodents or cell systems.

The human-evidence gap

Semax is used clinically in Russia, but by Western regulatory standards it is not an FDA-approved drug, and large, independent, controlled human trials in the international literature are limited. The mechanistic weight of the evidence is rodent.

The takeaway

Semax has a deep, coherent preclinical literature in brain gene expression and neuroprotection models. Its regulatory status differs by country, and the internationally available human evidence is thin.

Frequently Asked Questions

What is semax derived from?

A fragment of adrenocorticotropic hormone — ACTH(4-7) with a Pro-Gly-Pro tail — studied for central-nervous-system effects without ACTH’s hormonal activity.

What models is semax studied in?

Predominantly rat models of cerebral ischemia (stroke), plus more recent mouse spinal-cord-injury and Alzheimer’s models.

Is semax approved by the FDA?

No. It is used clinically in Russia but is not FDA-approved. American Peptides supplies it strictly for in vitro research.

What pathways do semax studies focus on?

Brain gene- and protein-expression changes related to the immune and vascular systems, neurotrophic signaling, and metal-ion/amyloid interactions.

Citations

Medvedeva EV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014. PubMed: PMID 24661604

Stavchansky VV, et al. “Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion.” Int J Mol Sci. 2021. PubMed: PMID 34201112

“Semax peptide targets the μ opioid receptor gene Oprm1 to promote functional recovery after spinal cord injury in female mice.” Br J Pharmacol. 2025. PubMed: PMID 40692165

“Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Aβ Aggregation and Amyloid Formation in Artificial Membrane Models.” ACS Chem Neurosci. 2022. PubMed: PMID 35080861

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Use / Administration Methods

Intranasal Spray (Primary Route): Semax is optimized for intranasal delivery, which provides rapid absorption through the nasal mucosa with direct access to the brain via the olfactory and trigeminal nerve pathways. This route bypasses first-pass hepatic metabolism and avoids the peptide degradation that occurs in the gastrointestinal tract. Semax is a particularly good candidate for nasal delivery because of its small molecular weight (seven amino acids), favorable formulation stability at physiological pH, and rapid absorption kinetics — properties that many larger peptides lack, which is why intranasal delivery produces unreliable results for most other peptides. To administer: clear nasal passages, tilt the head slightly forward, insert the spray tip into one nostril, and depress the pump once while breathing in gently. Alternate nostrils between doses. Avoid blowing the nose for at least 5 minutes after administration to allow absorption. Subcutaneous Injection (Less Common): Some research protocols and community users administer Semax via subcutaneous injection when using lyophilized powder. This route provides reliable systemic absorption but lacks the direct nasal-to-brain delivery advantage. Reconstitution (Lyophilized Powder): Allow the vial to reach room temperature Add bacteriostatic water slowly along the interior vial wall, do not jet directly onto the powder Gently swirl until dissolved; do not shake Common reconstitution ratio: 1:1 (e.g., 10 mg powder + 10 mL…
SIDE EFFECTS

Side Effects

Semax has demonstrated a favorable safety profile across both published research and decades of clinical use in Russia. No serious adverse events have been reported in published clinical or preclinical studies. Commonly Reported: Nasal irritation, burning sensation, or mild congestion (localized to the administration route) Headache (typically mild, may relate to initial neurotransmitter modulation) Sleep disturbance or insomnia (when administered too late in the day) Less Commonly Reported: Transient anxiety or restlessness (more common at higher doses; paradoxical given Semax's general anxiolytic trend) Nausea Dizziness Minor blood pressure fluctuations Drug Interactions: Semax affects both dopaminergic and serotonergic systems. Combining it with SSRIs, SNRIs, MAOIs, antipsychotics, or stimulant medications could produce amplified or unpredictable effects. No formal interaction studies exist, so co-administration with psychoactive drugs should proceed with caution and medical oversight. Unstudied Populations: Safety has not been evaluated in pregnancy, lactation, or in patients with significant hepatic or renal impairment. Long-term safety data in healthy populations using research-grade material remains limited. Sourcing Risks: As with all research peptides obtained outside regulated pharmaceutical supply chains, contamination and purity risks are separate from the compound's intrinsic safety profile. Independent third-party testing is advisable for any research-grade Sem…
02

Question drills

Open a question for its connected answer.

01Who is Semax for (And not for)?+

People who stand to gain the most benefit from Semax are those who have or are at risk for: Cognitive disorders: Semax’s nootropic properties may help increase one’s focus, memory, and capacity to learn. Cognitive diseases or dysfunctions: As a neuroprotectant, Semax is often administered post-stroke to aid in recovery, as well as in cases of age-related cognitive decline. Interestingly, despite its potential as an anxiolytic, Semax may not be indicated for people with anxiety disorders. In a 1996 study, researchers noted an “anxiogenic [anxiety-worsening] component in the spectrum of Semax’s behavioral effects” and suggested that the peptide would be optimally useful in people without elevated anxiety levels. 38 Other populations for whom Semax is contraindicated include people with diabetes (Semax may increase their blood sugar levels) and pregnant or breastfeeding women (there isn’t enough research to say whether Semax is safe for the developing fetus or child). 4

SOURCE / www.innerbody.com ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Researchers Cited in This Article

The researchers below authored or co-authored publications cited in this article. Listing them here identifies sources; it does not mean they wrote, independently reviewed, sponsored, or endorsed this PeptideDosages.com article. The site author is identified in the article byline.

RESEARCH

Additional Research Implications of Semax

Semax peptide appears to have a concentration-dependent effect on enkephalin-degrading enzymes of serum, exhibiting apparent pronounced effects compared to certain inhibitors of peptidases. Additionally, Semax speculatively inhibits histamine release from mast cell activation, suggesting potential anti-ulcer activity through stabilization of mast cells. In the realm of neuronal stimulation, research findings propose that Semax peptide may stimulate acetylcholine and exploratory activity. Researchers suggest that Semax peptide may improve the survival of cholinergic basal forebrain neurons in vitro, further stimulating choline acetyltransferase activity in dissociated basal forebrain tissue cultures without affecting the number of GABA-ergic neurons. Semax peptide might be a potentially relevant candidate for further research in studies on conditions such as ADHD and Rett syndrome. It is proposed that Semax may enhance the effects of psychostimulants on central dopamine release, trigger central brain-derived neurotrophic factor (BDNF) synthesis, and potentially improve selective attention and modulate brain development. The neuroprotective potential of Semax peptide may extend to the immune system, influencing microglia and immune system cells, particularly leukocyte activation. In the context of glaucomatous optic neuropathy, data suggests that a complex neuroprotective approaches, including Semax peptide exposure, may be employed in research models of normalized ophthalmic tone. The potential efficacy of the peptide may be attributed to Semax’s pathogenetic activity, with neuroprotective and neurotrophic effects speculated to contribute to the observed benefits.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Comparison to Related Compounds

Semax sits within a small family of nootropic research peptides derived from Russian neuroscience research programs. Understanding how the compound compares to related molecules h…

Comparison

Adamax vs Semax: Molecular Differences and Their Neural Impact

Small molecular differences between Adamax and Semax peptide may lead to different effects in research settings. Semax is well studied and is recognized for influencing BDNF signa…

Continue reading

Related articles